Twist Bioscience Co. (NASDAQ:TWST) Given Consensus Rating of “Buy” by Analysts

Twist Bioscience Co. (NASDAQ:TWST) has been assigned a consensus rating of “Buy” from the six research firms that are presently covering the firm, MarketBeat.com reports. Six equities research analysts have rated the stock with a buy rating. The average 12 month price target among brokerages that have covered the stock in the last year is $42.50.

TWST has been the topic of a number of recent research reports. Evercore ISI lifted their price target on shares of Twist Bioscience from $46.00 to $50.00 and gave the company an “outperform” rating in a research report on Friday, May 3rd. The Goldman Sachs Group raised shares of Twist Bioscience from a “neutral” rating to a “buy” rating and lifted their price target for the company from $25.00 to $45.00 in a research report on Wednesday, January 17th. Robert W. Baird boosted their target price on shares of Twist Bioscience from $39.00 to $40.00 and gave the stock an “outperform” rating in a research report on Friday, May 3rd. Barclays boosted their target price on shares of Twist Bioscience from $40.00 to $45.00 and gave the stock an “overweight” rating in a research report on Friday, May 3rd. Finally, Scotiabank boosted their target price on shares of Twist Bioscience from $43.00 to $48.00 and gave the stock a “sector outperform” rating in a research report on Monday.

Insider Activity at Twist Bioscience

In related news, insider William Banyai sold 798 shares of the company’s stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $37.13, for a total value of $29,629.74. Following the sale, the insider now directly owns 345,188 shares of the company’s stock, valued at $12,816,830.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, CEO Emily M. Leproust sold 1,487 shares of the company’s stock in a transaction on Wednesday, March 6th. The shares were sold at an average price of $37.43, for a total value of $55,658.41. Following the sale, the chief executive officer now directly owns 516,409 shares of the company’s stock, valued at $19,329,188.87. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider William Banyai sold 798 shares of the company’s stock in a transaction on Friday, May 3rd. The shares were sold at an average price of $37.13, for a total transaction of $29,629.74. Following the completion of the sale, the insider now directly owns 345,188 shares in the company, valued at $12,816,830.44. The disclosure for this sale can be found here. Insiders have sold 17,415 shares of company stock valued at $614,504 over the last ninety days. Corporate insiders own 3.92% of the company’s stock.

Institutional Trading of Twist Bioscience

Institutional investors have recently added to or reduced their stakes in the business. EdgeRock Capital LLC bought a new stake in Twist Bioscience during the fourth quarter valued at $30,000. Federated Hermes Inc. bought a new stake in Twist Bioscience during the third quarter valued at $29,000. China Universal Asset Management Co. Ltd. increased its stake in Twist Bioscience by 96.3% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,470 shares of the company’s stock valued at $30,000 after purchasing an additional 721 shares during the last quarter. Allspring Global Investments Holdings LLC increased its stake in Twist Bioscience by 51.8% during the third quarter. Allspring Global Investments Holdings LLC now owns 3,453 shares of the company’s stock valued at $70,000 after purchasing an additional 1,179 shares during the last quarter. Finally, Headlands Technologies LLC bought a new stake in Twist Bioscience during the first quarter valued at $124,000.

Twist Bioscience Stock Performance

Twist Bioscience stock opened at $43.20 on Friday. The company has a market cap of $2.52 billion, a price-to-earnings ratio of -12.86 and a beta of 1.64. Twist Bioscience has a 1 year low of $11.81 and a 1 year high of $44.92. The firm has a 50 day moving average price of $34.26 and a 200 day moving average price of $31.67.

Twist Bioscience (NASDAQ:TWST) last announced its quarterly earnings results on Thursday, May 2nd. The company reported ($0.79) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.84) by $0.05. The firm had revenue of $75.30 million for the quarter, compared to analysts’ expectations of $70.70 million. Twist Bioscience had a negative net margin of 69.24% and a negative return on equity of 31.61%. Twist Bioscience’s revenue was up 25.1% compared to the same quarter last year. During the same period in the previous year, the company posted ($1.06) earnings per share. Sell-side analysts predict that Twist Bioscience will post -3.17 EPS for the current year.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.